Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 12/20 | 0.79 |
| ▸ | TAS1R1 | Q7RTX1 | 11/20 | 0.79 |
| ▸ | TAS1R2 | Q8TE23 | 10/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638984 | 1.00 | TAS1R3 (0.79) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL13638898 | 0.97 | TAS1R3 (0.74) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL15983801 | 0.91 | NPC1 (0.73) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL704631 | 0.88 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL700898 | 0.86 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2ALDH1A1LMNA | |
| SCHEMBL13162940 | 0.85 | NPC1 (0.66) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL13193072 | 0.84 | NPC1 (0.59) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL27755168 | 0.84 | TAS1R3 (0.78) | TAS1R3TAS1R1TAS1R2NPC1RAB9A | |
| SCHEMBL700816 | 0.83 | TAS1R3 (0.73) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4174131 | 0.82 | TAS1R3 (0.68) | TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | TAS2R10, TAS2R50, TAS2R8 | TAS1R3 27/4885TAS1R1 23/4885TAS1R2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.